Stability of ceftolozane and tazobactam in different peritoneal dialysis solutions.

CONCLUSIONS: These results provide a platform for clinical studies to determine the safety and therapeutic efficacy of intraperitoneal C/T for the treatment of PDAP caused by resistant Pseudomonas species. PMID: 32052692 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32052692?dopt=Abstract

Source: Peritoneal Dialysis International - February 15, 2020 Category: Urology & Nephrology Tags: Perit Dial Int Source Type: research